Cancer Genetics Acquires vivoPharm
Combined Companies to Expedite Drug Development, Improving Lives of Patients Globally
With over a decade of experience and over 200 IND submissions for innovative therapies, vivoPharm’s addition is expected to be immediately accretive, adding considerable business opportunities in both pre-clinical studies, and immuno-oncology clinical trials, to further accelerate CGI’s strategy to be the premier partner of choice for oncology innovation and development from bench to bedside.
“This accretive acquisition immediately strengthens our market position as the premier partner for oncology therapeutic and diagnostic development while furthering our mission to change patient outcomes and improve industry insight into the mechanisms of oncology vivoPharm furthers our biopharma strategy and adds capabilities to enable our strategy to rescue and repurpose oncology drugs while providing us enhanced, revenue-generating capabilities across a broad and globally diverse client base.”
– Panna Sharma, President and CEO of Cancer Genetics, Inc.
“We are delighted that vivoPharm’s unique value proposition of integrated preclinical, safety and biomarker profiling, both in-vitro and in-vivo, have combined with Cancer Genetics and a team at the forefront of precision oncology development.”
– Dr. Ralf Brandt, CEO and Managing Director of vivoPharm
“We are delighted to unite vivoPharm and CGI’s businesses and capabilities to create an integrated bench to bedside service offering that will expedite drug development, improve the lives of patients worldwide and build value for company shareholders and employees.”
– Dr. Ian Nisbet, Chairman of vivoPharm